Hyperammonemia in patients with stable angina pectoris and nonalcoholic fatty liver disease at the steatosis stage

Author:

Zykina E. J.1,Simonova Zh. G.1ORCID

Affiliation:

1. Kirov state medical university of the Ministry of Health of the Russian Federation

Abstract

The aim. To assess the severity of hyperammoniemia in patients with non-alcoholic fatty liver disease at the steatosis stage in conditions of comorbidity with stable angina. Research materials and methods. During the clinical trial, three groups of patients with stable angina were formed. Group I (n = 43) consisted of patients with NAFLD at the stage of hepatic steatosis in combination with obesity and a stable form of CHD. Group II (n = 41) - patients with NAFLD at the stage of hepatic steatosis against the background of normal body weight and stable CHD. Group III (control) (n = 42) - patients with stable angina without NAFLD, with normal body weight. The results of laboratory examination (clinical and biochemical blood tests, lipidograms, insulin levels (calculated by HOMA-IR), glycosylated hemoglobin (HbAlc)) were evaluated; non-invasive markers for the diagnosis of liver injury. Hyperammonemia was evaluated by quantitative rapid ammonia analysis using a Pocket Chem TM BA PA-4140 analyzer. All patients underwent ultrasound of the liver using Philips Epiq 5 (USA). Results. In all patients with stable angina (group I and II), the diagnosis of non-alcoholic fatty liver disease, steatosis stage, was confirmed. The lipid profile of patients in Groups I and II showed more significant hypertriglyceridemia compared to those in the control group, with no statistical difference in Groups I and II. The mean ammonium level in patients with NAFLD in combination with stable CHD (group I, II) was above the threshold and was 87 (57-127.5) and 79 (57-97) μmol/L, respectively, and did not differ significantly (p > 0.05). In patients of group III (without liver disease), the mean values of ammonia in the blood were in the target range. According to the results of correlation analysis, we established the relationship of ammonium with liver enzymes, calculated steatosis indices and basic metabolic indicators. Conclusion. Patients with non-alcoholic fatty liver disease in the steatosis stage with a combination of stable angina have more severe hyperammonemia compared to patients with stable CHD without concomitant liver injury.

Publisher

LLC Global Media Technology

Subject

Gastroenterology,Hepatology

Reference16 articles.

1. Lazebnik L. B., Tarasova L. V., Komarova E. A., Busalaeva E. I. Effect of Helicobacter pylori infection on the course of non-alcoholic fatty liver disease. Experimental and clinical gastroenterology. 2019; 172(12): 90-94. (In Russ.) doi: 10.31146/1682-8658-ecg-172-12-90-94.@@ Lazebnik L. B., Tarasova L. V., Komarova E. A., Busalaeva E. I. Vliyanie infektsii Helicobacter pylori na techenie nealkogol'noi zhirovoi bolezni pecheni. Eksperimental'naya i klinicheskaya gastroenterologiya. 2019; 172(12): 90-94. doi: 10.31146/1682-8658-ecg-172-12-90-94.

2. Diomidova V.N., Tarasova L. V., Trukhan D. I., et al. Information value of shear wave elastography with elastometry in non-alcoholic fatty liver disease. Practical medicine. 2018; 112(1): 81-85. (In Russ.).@@ Diomidova V. N., Tarasova L. V., Trukhan D. I. i dr. Informativnost' elastografii sdvigovoi volnoi s elastometriei pri nealkogol'noi zhirovoi bolezni pecheni. Prakticheskaya meditsina. 2018; 112(1): 81-85.

3. Drapkina O. M., Korneeva O. N. Continuium of non-alcoholic fatty liver disease: from hepatic steatosis to cardiovascular risk. Rational pharmacotherapy in cardiology. 2016; 12 (4): 424-429. (In Russ.) doi:10.20996/1819-6446-2016-12-4-424-429.@@ Drapkina O. M., Korneeva O. N. Kontinium nealkogol'noi zhirovoi bolezni pecheni: ot steatoza pecheni do serdechno-sosudistogo riska. Ratsional'naya farmakoterapiya v kardiologii. 2016; 12 (4): 424-429. doi: 10.20996/1819-6446-2016-12-4-424-429.

4. Ivashkin V. T., Mayevskaya M. V., Pavlov Ch. S, Tikhonov I. N. et al. Clinical recommendations for the diagnosis and treatment of non-alcoholic fatty liver disease of the Russian Society for the Study of Liver and the Russian Gastroenterological Association.Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(2):24-42. (In Russ.) Doi: 10.22416/1382-4376-2016-26-2-24-42.@@ Ivashkin V. T., Maevskaya M. V., Pavlov Ch. S., Tikhonov I. N. i dr. Klinicheskie rekomendatsii po diagnostike i lecheniyu nealkogol'noi zhirovoi bolezni pecheni Rossiiskogo obshchestva po izucheniyu pecheni i Rossiiskoi gastroenterologicheskoi assotsiatsii. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii. 2016;26(2):24-42. Doi: 10.22416/1382-4376-2016-26-2-24-42.

5. Janssen A., Grobbee D., Dendale P. Non-alcoholic fatty liver disease, a new and growing risk indicator for cardiovascular disease. European Journal of Preventive Cardiology. 2020; 27 (10): 1059-1063. doi: 10.1177/2047487319891783.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Sarcopenia and non-alcoholic fatty liver disease;Experimental and Clinical Gastroenterology;2024-03-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3